Sanofi’s Blood Disorder Drug Cablivi Gets Approval in Europe
Sanofi SNY announced that the European Commission has approved a rare blood disorder drug, Cablivi (caplacizumab) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). This is the first drug to receive approval for this indication. This may help the drug to gain leading market share with first-mover advantage in this indication. […]